Organization | Fujifilm

Fujifilm Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Tokyo Japan (1934)

Status: No NME R&D (1934)

Organization Overview

First Clinical Trial

2014

NCT02193958

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cellular Dynamics International, Inc. - A FUJIFILM Company | Fuji Film | Fujifilm Pharmaceuticals U.S.A., Inc. | Japan Regenerative Medicine Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (10)

Key: Fujifilm (1) Acquired (9)

autologous cardiac stem cells (1 trial)

azithromycin (zithromax) (1 trial)

diclofenac (voltaren) (1 trial)

esflurbiprofen (1 trial)

favipiravir (2 trials)

hydroxychloroquine (plaquenil) (1 trial)

ozoralizumab (1 trial)

t-614 (1 trial)

ts-142 (14 trials)

zinc sulfate (1 trial)

Drugs in Phase 2 Trials (11)

Key: Fujifilm (6) Acquired (5)

azacitidine (vidaza) (1 trial)

ff-10101-01 (1 trial)

ff-10501-01 (2 trials)

ff-10502-01 (1 trial)

gemcitabine (gemzar) (2 trials)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (10)

Key: Fujifilm (2) Acquired (8)

ff21101 (1 trial)

itraconazole (sporanox) (1 trial)

moxifloxacin (avelox) (1 trial)

pf-04802540 (3 trials)

tasp0410699 (1 trial)

topotecan (hycamtin) (1 trial)

ts-134 (3 trials)

ts-143 (3 trials)

ts-172 (1 trial)

zopiclone (Zimovane) (1 trial)

Drugs in Other Trials (1)

whole blood (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hypoplastic Left Heart Syndrome (Phase 3)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 2)

Preleukemia (Phase 2)

Syndrome (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 50
# of Trial APIs: 32